Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

A Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03493945

Enrollment

Registered

2018-04-11

Start date

2018-05-01

Completion date

2024-10-08

Last updated

2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer

Keywords

Immunotherapy, Combined Treatment, PD-1/PD-L1, Tumor-Specific T Cells, Novel Cancer Vaccine

Brief summary

Background: Immunotherapy drugs help the body to fight cancer. Scientists think that combining some of these drugs will make them work better than when used alone. This may be true for many types of cancer, including castration-resistant prostate cancer (CRPC). Objective: To test if any of the combinations of drugs below have anti-prostate cancer activity and to test if they are safe. 1. Bavarian-Nordic (BN)-brachyury, bintrafusp alfa (M7824). 2. Bavarian-Nordic (BN)-brachyury, bintrafusp alfa (M7824) + Anktiva (N-803). 3. Bavarian-Nordic (BN)-brachyury, bintrafusp alfa (M7824) + Anktiva (N-803) + Epacadostat. Eligibility: People ages 18 and older with CRPC or another metastatic cancer Design: Participants will be screened with: * Medical history * Physical exam * Computed tomography (CT) or magnetic resonance imaging (MRI) scans * Possible bone imaging * Blood, urine, and heart tests * Possible tumor biopsy Participants will be treated with a 2-, 3- or 4-drug combinations of the following study drugs in 2-week cycles: * Participants will receive M7824 by intravenous (IV) once every 2 weeks. * Participants will receive N-803 by injection once every 2 weeks. They will record any skin changes at the injection site in a diary. * Participants will receive BN-brachyury as 4 injections to different limbs. They will get the first 3 doses 2 weeks apart. Then they will get doses every 4 weeks for 6 months, then every 3 months for 2 years, then every 6 months. * Participants will take Epacadostat orally every 12 hours. They will keep a pill diary. Participants will have physical exams and blood and urine tests at the start of each cycle. They may have scans every 12 weeks. Participants will continue treatment until their disease gets worse or they cannot tolerate the side effects. Participants will have a follow-up visit 4-5 weeks after they stop treatment. They will have a physical exam and blood tests. They may be asked to return for scans every 3 months.

Detailed description

Background: * Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) signaling appears to be a major inhibitor of activated T cell anti-tumor immune responses. The rapid, deep and durable responses seen in various malignancies with PD-1/PD-L1 targeted agents demonstrate that blockade of this axis is key to facilitating immune responses within the tumor microenvironment (TME). * Prostate cancer is poorly recognized by T cells. Lack of an immune response is one explanation for the lower response rates (\<15%) observed with anti-PD-1/PD-L1 therapies for prostate cancer. * Increasing response rates will likely require therapeutic nullification of multiple immune deficits by combining immunotherapies that generate tumor-specific T cells (vaccine), dampen the inhibitory milieu of the TME, and enhance T and natural killer (NK) cell activity within the TME. * A quick efficacy seeking trial, utilizing sequential arms offers a means to identify signals of activity for combinations of immunotherapy, added sequentially, in castration resistant prostate cancer (CRPC) participants. * Bavarian Nordic (BN)-Brachyury is a novel recombinant vector-based therapeutic cancer vaccine designed to induce an enhanced immune response against brachyury, which is overexpressed in many solid tumor types, including prostate adenocarcinoma. BN-Brachyury collectively refers to the priming doses (modified vaccinia Ankara (MVA)-BN-Brachyury) and the boost doses (fowlpox virus (FPV)-Brachyury) of the vaccine platform. * bintrafusp alfa (M7824) is a bifunctional fusion protein consisting of an anti-programmed death ligand 1 (PD-L1) antibody and the extracellular domain of transforming growth factor beta (TGF- beta) receptor type 2, a TGF-beta trap. M7824 can also mediate antibody-dependent cellular cytotoxicity in vitro. * Anktiva (N-803) is an interleukin 15 (IL-15)/IL-15R alpha superagonist complex that can enhance NK cell mediated antibody-dependent cell-mediated cytotoxicity (ADCC) and T-cell cytotoxicity. * Synergistic anti-tumor effects have been observed in vitro when combining M7824 and N-803, and in vivo when combining these agents with tumor vaccine in animal models. * Indoleamine 2,3-dioxygenase 1 (IDO1) is overexpressed in many solid tumors and can contribute to immune escape by tumor cells. INCB024360 (Epacadostat) is an IDO1 inhibitor under investigation in combination with different immunotherapies in treatment of various malignancies. * In treating of CRPC, we hypothesize that these agents and their effects will be complementary. Tumor-specific T cells generated by vaccine may become more functional in a TME following treatment with M7824 and Epacadostat. N-803 can further enhance the activity of antigen-specific T cells as well as NK cells. Objective: -To determine if there is clinical benefit to any of a set of 3 possible treatments for participants with CRPC: * BN-Brachyury + M7824 * BN-Brachyury + M7824 + N-803 * BN-Brachyury + M7824 + N-803 + Epacadostat Eligibility: * Adults with histologically proven CRPC, or metastatic solid tumor of any type for which there is no standard treatment or standard treatment has failed. * Adequate organ function as defined by liver, kidney, and hematologic laboratory testing. * Participants with acquired immune defects, active systemic autoimmune disease, history of organ transplant, history of chronic infections, or history of active inflammatory bowel disease are excluded. Design: Open label Phase I/II trial with following randomization during the expansion. Phase I: Cohort 1, Arm 1.1 -Up to 18 participants with any solid tumor will be enrolled in dose escalation Cohort 1 for treatment in Arm 1.1 (flat dose of M7824 + different dose levels of N-803). Phase IIA: expansion with sequential enrollment into Cohort 2A, Arms 2.1A, 2.2A and 2.3 A * Concurrently with the enrollment to Arm 1.1, 13 participants with CRPC will start enrollment in Cohort 2A for treatment in Arm 2.1A (M7824 + BN-Brachyury). * When safe dosing of N-803 is identified during Phase I, 13 participants have enrolled in arm 2.1A and the first 6 participants, treated in Arm 2.1A, have met safety requirements, 13 participants with CRPC will start enrollment in Cohort 2A for treatment in Arm 2.2A (M7824 + BN-Brachyury + N-803). * When 13 participants have enrolled in Arm 2.2A and the first 6 participants, treated in Arm 2.2A, have met safety requirements, 13 participants with CRPC will start enrollment in Cohort 2A for treatment in Arm 2.3A (M7824 + BN-Brachyury + N-803 + Epacadostat). Phase IIB: expansion with randomized enrollment into Cohorts 2D and 2R, Arms 2.1B, 2.2B. and 2.3B * Each Arm in Cohorts 2D and 2R: 2.1B, 2.2B and 2.3B will be open for additional enrollment (25 evaluable participants total) when the initial 13 participants have accrued, safety requirements are meet and a positive signal (defined as Objective Response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or sustained prostate-specific antigen (PSA) decrease \>= 30% sustained for \> 21 days) in \>= 2 participants is shown. * If only one arm is open for additional enrollment, participants will be directly assigned to this arm. If 2 arms are open for additional enrollment, participants will be randomized between these 2 open arms. If 3 arms are open for additional enrollment, participants will be randomized among these 3 open arms. If there are \>= 6 of 25 participants with a positive signal of activity in any expansion arm, that arm will be considered of interest for future studies.

Interventions

BIOLOGICALM7824

1,200 mg intravenous (IV) once every 2 weeks.

DRUGN-803

8-15 mcg/kg subcutaneous every 2 weeks.

BIOLOGICALMVA-BN-Brachyury

MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).

BIOLOGICALFPV-Brachyury

FPV-Brachyury will be given 2 weeks after second dose of modified vaccinia Ankara (MVA)-Bavarian Nordic (BN)-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 months.

DRUGEpacadostat

600 mg orally twice daily (1200 MG total).

DRUGAcetaminophen

Antipyretic medication, orally, prior to infusion, up to 650mg.

DRUGIbuprofen

Antipyretic medication, orally, prior to infusion, up to 600mg.

DRUGNaproxen

Antipyretic medication, orally, prior to infusion, up to 500mg.

OTHERBenadryl

50mg orally prior to infusion.

DIAGNOSTIC_TESTEKG

Baseline and principal investigator discretion.

DIAGNOSTIC_TESTBone scan

Restaging every 12 weeks.

DIAGNOSTIC_TESTCT chest, abdomen and pelvis

Every 12 weeks after start of therapy.

DIAGNOSTIC_TESTMRI

If clinically indicated.

Study design

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

* INCLUSION CRITERIA: Participants must have histologically or cytologically confirmed any solid tumor (Cohort 1) or castration-resistant prostate cancer (CRPC), Cohorts 2A, 2D and 2R). For the Cohort 1, eligible participants must have a histologically, cytologically or radiographically proven metastatic or locally advanced solid tumor of any type, for which there is no curative standard therapy or standard therapy has failed. Castrate testosterone level (less than 50ng/dl or 1.7nmol/L). (Participants with a malignancy other than prostate cancer are excluded from this criterion). Radiological confirmation of metastatic disease, or Progressive disease at study entry defined as one or more of the following criteria occurring in the setting of castrate levels of testosterone: --Radiographic progression defined as any new or enlarging bone lesions or growing lymph node disease, consistent with prostate cancer OR --prostate-specific antigen (PSA) progression defined by sequence of rising values separated by greater than 1 week (2 separate increasing values over a minimum of 1 ng/ml (Prostate Cancer Clinical Trials Working Group 3 (PCWG3) PSA eligibility criteria). If participants had been on flutamide, PSA progression is documented 4 weeks or more after withdrawal. For participants on bicalutamide or nilutamide disease progression is documented 6 or more weeks after withdrawal. The requirement for a 4-6 week withdrawal period following discontinuation of flutamide, nilutamide or bicalutamide only applies to participants who have been on these drugs for at least the prior 6 months. For all other participants they must stop bicalutamide, nilutamide or flutamide the day prior to enrollment. Asymptomatic or mildly symptomatic form prostate cancer; no use of regularly scheduled opiate analgesics for prostate cancer-related pain. (Participants with a malignancy other than prostate cancer are excluded from this criterion). Participants must agree to continuation of androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone analogue/antagonist or bilateral orchiectomy. (Participants with a malignancy other than prostate cancer are excluded from this criterion). Participants may also continue oral androgen receptor antagonist/anti-androgen therapy (e.g. enzalutamide or abiraterone) unless enrolling to Arm 2.3A or 2.3B due to concerns regarding Cytochrome P450 (CYP)mediated drug-drug interactions epacadostat. Participants must have had the following prior therapy: Testosterone lowering therapy for castration-resistant prostate cancer (CRPC) In addition to continuation of androgen deprivation therapy (ADT) (unless status post bilateral orchiectomy) eligible patients must have received and had PSA or radiographic progression on enzalutamide (or other oral androgen receptor antagonist e.g. darolutamide or apalutamdide) or abiraterone acetate. Participants who have tumors known to be microsatellite instability high/mismatch repair deficient or tumor mutational burden high must have received prior pembrolizumab. Participants with known pathogenic homologous recombination repair mutations for which there is evidence of benefit with poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors (e.g. BReast CAncer gene 1 (BRCA1). BReast CAncer gene 2 (BRCA2), ataxia-telangiectasia mutated (ATM) must have received prior PARP inhibitor. Age greater than or equal to 18 years. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1 Participants must have adequate organ and marrow function as defined below: * Absolute neutrophil count greater than or equal to 1000/mcL * Platelets greater than or equal to 100,000/mcL * Hemoglobin greater than or equal to 9.0 g/dL * Total bilirubin within normal institutional limits; in participants with Gilbert's, less than or equal to 3.0 mg/dL * Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) less than or equal to 2.5X upper limit of normal. For subjects with liver involvement in their tumor, AST less than or equal to 3.5. X upper limit of normal (ULN), ALT less than or equal to 3.5 X ULN, and bilirubin less than or equal to 3.0 is acceptable * Creatinine within 1.5X upper limit of normal institutional limits The effects of Bavarian Nordic (BN)-Brachyury, bintrafusp alfa (M7824), Anktiva (N-803), and Epacadostat on the developing human fetus are unknown. For this reason, men and women must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study and maintain such contraception until 4 months following the last dose of any study agent. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her partner s treating physician immediately. Ability of subject to understand and the willingness to sign a written informed consent document. Participants with successfully treated hepatitis C virus (HCV) are eligible if HCV viral load is undetectable.

Exclusion criteria

Participants who are immunocompromised as follows: * Human immunodeficiency virus positivity due to the potential for decreased tolerance, and potential to be at risk for severe side effects with immunotherapies. These concerns are relevant to all drugs, as drug-drug interactions among antiretrovirals and immunotherapies are yet uncharacterized. * Chronic administration (defined as daily or every other day for continued use greater than 14 days) of systemic corticosteroids or other immune suppressive drugs, within 28 days before treatment on study. Nasal, or inhaled steroid, topical steroid creams and eye drops for small body areas are allowed. Physiologic doses of steroids are permitted, e.g., a participant taking hydrocortisone for adrenal insufficiency or a patient recently on abiraterone (administered with 10 mg of prednisone daily) who is tapering off of prednisone is allowed to continue that taper. * Participants who have undergone allogeneic peripheral stem cell transplantation, or solid organ transplantation requiring immunosuppression * Active autoimmune disease, except participants with type 1 diabetes mellitus, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring current immunosuppression, or with other endocrine disorders on replacement hormones or are not excluded if the condition is well controlled. Prostate cancer participants with a history of brain/leptomeningeal metastasis, since these participants have a very poor prognosis, and immunotherapy may take time to lead to beneficial clinical effects. Participants with brain or CNS metastases enrolling to arm 1.1 are eligible if they are status post definitive radiotherapy or surgery, and are asymptomatic History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents to be used in the cohort the subject will be enrolled into. Known allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin). Any condition which, in the opinion of the investigator, would prevent full participation in this trial (including the long-term follow-up), or would interfere with the evaluation of the trial endpoints. Participants with prior investigational drug, chemotherapy, immunotherapy or any prior radiotherapy (except for palliative bone directed therapy) within the past 28 days prior to enrollment, except if the investigator has assessed that all residual treatment-related toxicities have resolved or are minimal and feel the participant is otherwise suitable for enrollment. Uncontrolled intercurrent acute or chronic illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (\>New York Heart Association Class I), hepatic disease, unstable angina pectoris, serious cardiac arrhythmia, requiring medication, uncontrolled hypertension (Systolic blood pressure (SBP) \>170/ diastolic blood pressure (DBP)\>105) or psychiatric illness/social situations within 12 months that would limit compliance with study requirements. Use of herbal products that may decrease PSA levels (e.g., saw palmetto) Participants who have had cytotoxic chemotherapy for metastatic castration-resistant prostate cancer within the past 3 months. (Participants who have had docetaxel for metastatic castration sensitive per Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) data may enroll as long as they did not have progressive disease while on docetaxel and are 3 months removed from treatment, with all treatment related toxicities resolving to at least grade 1.) Participants who have undergone major surgery within 4 weeks of enrollment. A biopsy will not preclude a participant from starting study. Participants with a history of hepatitis B (HBV) are excluded due to potential risk for viral reactivation and resulting liver injury in persons with latent HBV Subjects unwilling to accept blood products or blood transfusions as medically indicated. As there is a risk of severe bleeding with M7824, participants must be willing to receive blood transfusions if medically necessary for their own safety For participants enrolling in Arm 2.3A and for participants who may be randomized to Arm 2.3B, the following additional

Design outcomes

Primary

Measure	Time frame	Description
Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Within 21 days of the start of treatment	A DLT is defined as any of the following adverse events (AE) possibly related to study drugs that occur within 21 days of the start of treatment. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 3 is moderate. Grade 4 is life-threatening, and Grade 5 is death related to AE. A DLT is any grade ≥ 4 hematologic toxicity or grade 3 thrombocytopenia with associated bleeding; any grade ≥ 3 non-hematologic toxicity, except for any of the following: transient (≤ 48 hour) grade 3 fatigue, local reactions, flu-like symptoms, fever, headache, or nausea, emesis, and diarrhea; or CTCAE Grade 3 skin toxicity lasting less than five days. A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, or congenital anomaly/birth defect.
Clinical Benefit With Any of a Set of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Reported With an 80% Confidence Interval	From enrollment up to 49 weeks	Objective clinical response and/or prostate-specific antigen (PSA) decline of \>=30% sustained for a minimum of 21 days. Any of these is considered 'clinical benefit.' Objective response was assessed by the response evaluation criteria in solid tumors (RECIST) 1.1. Complete response (CR) is disappearance of all non-target lesions and normalization of tumor marker level. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive disease (PD) is at least a 20% increase in the sum of the diameters of target lesions. Three treatments evaluated are: Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824), Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824) + Anktiva (N-803), and Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824) + Anktiva (N-803) + Epacadostat.
Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	From enrollment up to 49 weeks	Objective response was assessed by the response evaluation criteria in solid tumors (RECIST) 1.1. Complete response (CR) is disappearance of all non-target lesions and normalization of tumor marker level. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive disease (PD) is at least a 20% increase in the sum of the diameters of target lesions. Three treatments evaluated are: Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824), Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824) + Anktiva (N-803), and Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824) + Anktiva (N-803) + Epacadostat.

Secondary

Measure	Time frame	Description
Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	3 weeks dose-limiting toxicity (DLT) period	Number of participants with grades 3 4, and/or 5 serious adverse events related to treatment treated with combinations and Bintrafusp alfa (M7824) + Anktiva (N-803).
6-month Progression Free Survival (PFS) Probability	6-months	6-month progression free survival was measured from the on-study date until progression or death without progression in participants and reported with a 95% confidence interval. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions.
Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	3 weeks dose-limiting toxicity (DLT) period	Number of participants with grades 1, 2, 3, and 4 non-serious adverse events related to treatment treated with combinations and Bintrafusp alfa (M7824) + Anktiva (N-803).

Other

Measure	Time frame	Description
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	Adverse Events were monitored/assessed from the first study intervention, up to 49 weeks.	Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Phase (Ph) I Dose Escalation, Cohort 1, Arm 1.1, Dose Level (DL) 1 Phase I Dose Escalation, Cohort 1, Arm 1.1, Dose Level 1 Participants with any solid tumor M7824 + N-803 (accrual closed) N803 Dose Level 1 =10mcg/kg, M7824 Dose Level 1 =1200mg	4
Phase I Dose Escalation, Cohort 1, Arm 1.1 Dose Level 2 Phase I Dose Escalation, Cohort 1, Arm 1.1 Dose Level 2 Participants with any solid tumor M7824 + N-803 (accrual closed) N803 Dose Level 2 = 15mcg/kg M7824 Dose Level 2=1200mg	10
Phase I Dose Escalation, Cohort 1: Enrolled But Not Treated Phase I Dose Escalation, Cohort 1 Participants with any solid tumor M7824 + N-803 (accrual closed)	1
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A Phase IIA Dose Expansion, Cohort 2, Arm 2.1A Participants with castration-resistant prostate cancer (CRPC) during Phase IIA M7824 + BN-Brachyury	13
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A Phase IIA Dose Expansion, Cohort 2, Arm 2.2A Participants with CRPC during Phase IIA M7824 + BN-Brachyury + N-803 during phase IIA N803 Dose Level 2 = 15mcg/kg M7824 Dose Level 2=1200mg	13
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B Phase IIB Dose Expansion, Cohort 2, Arm 2.B Participants with CRPC requiring randomization in phase IIB M7824 + BN-Brachyury during phase IIB + N803 Dose Level 2 = 15mcg/kg M7824 Dose Level 2=1200mg	12
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A Participants with CRPC during Phase IIA M7824 + BN-Brachyury + N-803 + Epacadostat during phase IIA	6
Total	59

Withdrawals & dropouts

Period	Reason	FG001	FG002	FG003	FG004	FG005
Phase I Dose Escalation	Ineligible	0	1	0	0	0
Phase I Dose Escalation	New therapy	1	0	0	0	0
Phase II Dose Expansion	Refused further treatment	0	0	0	1	1
Phase II Dose Expansion	Switched to alternative therapy	0	0	3	0	0

Baseline characteristics

Characteristic	Phase I Dose Escalation, Cohort 1, Arm 1.1 Dose Level 2	Phase I Dose Escalation, Cohort 1: Enrolled But Not Treated	Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Phase (Ph) I Dose Escalation, Cohort 1, Arm 1.1, Dose Level (DL) 1	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	1 Participants	0 Participants	8 Participants	7 Participants	6 Participants	5 Participants	1 Participants	28 Participants
Age, Categorical Between 18 and 65 years	9 Participants	1 Participants	5 Participants	6 Participants	6 Participants	1 Participants	3 Participants	31 Participants
Age, Continuous	52.34 years STANDARD_DEVIATION 12.05	50.5 years STANDARD_DEVIATION 0	67.81 years STANDARD_DEVIATION 9.23	65.69 years STANDARD_DEVIATION 6.81	66.57 years STANDARD_DEVIATION 6.97	75.47 years STANDARD_DEVIATION 8.44	54.23 years STANDARD_DEVIATION 12.56	64.03 years STANDARD_DEVIATION 11.19
Ethnicity (NIH/OMB) Hispanic or Latino	2 Participants	0 Participants	1 Participants	2 Participants	0 Participants	0 Participants	1 Participants	6 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	7 Participants	1 Participants	12 Participants	9 Participants	12 Participants	6 Participants	3 Participants	50 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	3 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	2 Participants
Race (NIH/OMB) Black or African American	0 Participants	0 Participants	4 Participants	1 Participants	5 Participants	0 Participants	0 Participants	10 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants	0 Participants	0 Participants	3 Participants	0 Participants	0 Participants	0 Participants	4 Participants
Race (NIH/OMB) White	9 Participants	1 Participants	8 Participants	8 Participants	7 Participants	6 Participants	3 Participants	42 Participants
Region of Enrollment United States	10 participants	1 participants	13 participants	13 participants	12 participants	6 participants	4 participants	59 participants
Sex: Female, Male Female	4 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	3 Participants	8 Participants
Sex: Female, Male Male	6 Participants	0 Participants	13 Participants	13 Participants	12 Participants	6 Participants	1 Participants	51 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	1 / 4	2 / 10	1 / 13	0 / 13	0 / 12	0 / 6
other Total, other adverse events	4 / 4	10 / 10	13 / 13	13 / 13	12 / 12	6 / 6
serious Total, serious adverse events	3 / 4	5 / 10	8 / 13	5 / 13	3 / 12	2 / 6

Outcome results

Primary

Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval

Objective response was assessed by the response evaluation criteria in solid tumors (RECIST) 1.1. Complete response (CR) is disappearance of all non-target lesions and normalization of tumor marker level. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive disease (PD) is at least a 20% increase in the sum of the diameters of target lesions. Three treatments evaluated are: Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824), Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824) + Anktiva (N-803), and Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824) + Anktiva (N-803) + Epacadostat.

Time frame: From enrollment up to 49 weeks

Population: 43/59 participants were analyzed because 14 were not applicable for this endpoint per protocol, 1 was ineligible, and 1 was not able to be assessed for this endpoint because participant withdrew from the study before having efficacy assessments.

Arm	Measure	Group	Value (NUMBER)
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Complete Response	0 Proportion of participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Progressive Disease	0.67 Proportion of participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Stable Disease	0.33 Proportion of participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Partial Response	0 Proportion of participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Progressive Disease	0.67 Proportion of participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Stable Disease	0 Proportion of participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Partial Response	0.33 Proportion of participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Complete Response	0 Proportion of participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Stable Disease	0 Proportion of participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Partial Response	0 Proportion of participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Complete Response	0 Proportion of participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval	Progressive Disease	1 Proportion of participants

Primary

Clinical Benefit With Any of a Set of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Reported With an 80% Confidence Interval

Objective clinical response and/or prostate-specific antigen (PSA) decline of \>=30% sustained for a minimum of 21 days. Any of these is considered 'clinical benefit.' Objective response was assessed by the response evaluation criteria in solid tumors (RECIST) 1.1. Complete response (CR) is disappearance of all non-target lesions and normalization of tumor marker level. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive disease (PD) is at least a 20% increase in the sum of the diameters of target lesions. Three treatments evaluated are: Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824), Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824) + Anktiva (N-803), and Phase II Bavarian Nordic (BN) Brachyury + Bintrafusp alfa (M7824) + Anktiva (N-803) + Epacadostat.

Time frame: From enrollment up to 49 weeks

Population: 43/59 participants were analyzed because 14 were not applicable for this endpoint per protocol, 1 was ineligible and 1 was not able to be assessed for this endpoint because participant withdrew from the study before having efficacy assessments.

Arm	Measure	Value (NUMBER)
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Clinical Benefit With Any of a Set of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Reported With an 80% Confidence Interval	.076 Proportion of participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Clinical Benefit With Any of a Set of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Reported With an 80% Confidence Interval	0.292 Proportion of participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Clinical Benefit With Any of a Set of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Reported With an 80% Confidence Interval	0 Proportion of participants

Primary

Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)

A DLT is defined as any of the following adverse events (AE) possibly related to study drugs that occur within 21 days of the start of treatment. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 3 is moderate. Grade 4 is life-threatening, and Grade 5 is death related to AE. A DLT is any grade ≥ 4 hematologic toxicity or grade 3 thrombocytopenia with associated bleeding; any grade ≥ 3 non-hematologic toxicity, except for any of the following: transient (≤ 48 hour) grade 3 fatigue, local reactions, flu-like symptoms, fever, headache, or nausea, emesis, and diarrhea; or CTCAE Grade 3 skin toxicity lasting less than five days. A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, or congenital anomaly/birth defect.

Time frame: Within 21 days of the start of treatment

Population: 58/59 participants were analyzed because 1 was ineligible.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 4	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 3	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 5	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 4	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 3	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 5	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 5	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 3	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 4	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 5	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 3	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 4	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 3	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 4	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 5	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 4	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 5	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)	Grade 3	0 Participants

Secondary

6-month Progression Free Survival (PFS) Probability

6-month progression free survival was measured from the on-study date until progression or death without progression in participants and reported with a 95% confidence interval. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions.

Time frame: 6-months

Arm	Measure	Value (MEDIAN)
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	6-month Progression Free Survival (PFS) Probability	0.354 proportion probability
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	6-month Progression Free Survival (PFS) Probability	0.348 proportion probability
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	6-month Progression Free Survival (PFS) Probability	NA proportion probability

Secondary

Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)

Number of participants with grades 1, 2, 3, and 4 non-serious adverse events related to treatment treated with combinations and Bintrafusp alfa (M7824) + Anktiva (N-803).

Time frame: 3 weeks dose-limiting toxicity (DLT) period

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever probably related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to M7824	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify probably related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin induration definitely related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alkaline phosphatase increased possibly related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to research	4 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to research	2 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to research	2 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyponatremia probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified incl cysts and polyps probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other, specify, probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone increased probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to M7824	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 injection site reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to M7824	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders and administration site conditions-Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to research	2 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Neutrophil count decreased	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dehydration possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain definitely related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified Other specify probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders& administration site conditions Other specify probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to M7824	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to M7824	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders and administration site conditions probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders& administration site conditions Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to M7824	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to M7824	2 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to research	2 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Anktiva (N803)0	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Sinusitis possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Headache possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Edema limbs definitely related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to research	3 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to research	2 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to research	1 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized edema probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders other specify probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculopapular possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to M7824	2 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders& administration site conditions Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to research	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to M7824	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to research	3 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Anktiva (N803)0	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Sinusitis possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to research	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Neutrophil count decreased	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Headache possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders Other specify probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculopapular possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Edema limbs definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders other specify probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to research	8 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to research	5 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders - Other specify probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to research	7 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia probably related to research	3 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to M7824	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue probably related to research	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 injection site reaction definitely related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to M7824	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alkaline phosphatase increased possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to research	3 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to research	9 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin induration definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to research	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to research	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone increased probably related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to M7824	3 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to research	3 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to research	3 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified incl cysts and polyps probably related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders - Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified Other specify probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized edema probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders& administration site conditions Other specify probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyponatremia probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to M7824	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders and administration site conditions-Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders - Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other, specify, probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to M7824	3 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dehydration possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to M7824	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders and administration site conditions probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to M7824	3 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis definitely related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Epacadostat	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to M7824	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify definitely related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to research	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to research	3 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to research	2 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Anktiva (N803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to research	3 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify definitely related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to M7824	6 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders and administration site conditions-Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders Other specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders& administration site conditions Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized edema probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to research	4 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify definitely related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin induration definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dehydration possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Sinusitis possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyponatremia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	9 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders definitely related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Anktiva (N803)0	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to M7824	3 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders and administration site conditions probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculopapular possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify possibly related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Edema limbs definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Neutrophil count decreased	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders& administration site conditions Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other, specify, probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	3 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified incl cysts and polyps probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	5 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to research	5 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Headache possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to research	9 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alkaline phosphatase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify possibly related to M7824	3 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 injection site reaction definitely related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	4 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to Bavarian-Nordic (BN)-brachyury	5 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to M7824	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify possibly related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders - Other specify probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified incl cysts and polyps probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to research	5 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to research	6 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to research	10 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Headache possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Sinusitis possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 injection site reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders - Other specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin induration definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders& administration site conditions Other specify probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to M7824	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized edema probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to M7824	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders and administration site conditions probably related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to research	5 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders& administration site conditions Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to M7824	5 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Anktiva (N803)0	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to M7824	4 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to M7824	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dehydration possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to M7824	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyponatremia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	7 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify possibly related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Edema limbs definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to research	5 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Bavarian-Nordic (BN)-brachyury	4 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	6 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to Bavarian-Nordic (BN)-brachyury	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders - Other specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculopapular possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders other specify probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify possibly related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders and administration site conditions-Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other, specify, probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alkaline phosphatase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Anktiva (N803)	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to research	4 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Epacadostat	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to research	7 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders Other specify probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Neutrophil count decreased	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other, specify, probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculopapular possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders& administration site conditions Other specify probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders - Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Neutrophil count decreased	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alkaline phosphatase increased possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders& administration site conditions Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders - Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders other specify probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Edema limbs definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders and administration site conditions probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders and administration site conditions-Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 injection site reaction definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Sinusitis possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified incl cysts and polyps probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Anktiva (N803)0	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders Other specify probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyponatremia probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Epacadostat	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized edema probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified Other specify probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone increased probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin induration definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain definitely related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dehydration possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Headache possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Anktiva (N803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders - Other specify probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Epacadostat	4 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dehydration possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Epacadostat	3 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Metabolism and nutrition disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Headache possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anal hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anemia probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemorrhoidal hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to Anktiva (N803)	3 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized edema probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyponatremia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin induration definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry skin possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Musculoskeletal and connective tissue disorder Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other specify definitely related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypotension probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders and administration site conditions-Other specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Thyroid stimulating hormone possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Paresthesia definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Small intestine ulcer possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperkeratosis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemoglobinuria definitely related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Edema limbs definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Epacadostat	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Anemia possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pain probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Sinusitis possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lymphocyte count decreased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Nausea probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperhidrosis possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria possibly related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Serum amylase probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders - Other specify definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Periorbital edema probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bullous dermatitis definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders and administration site conditions probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Cystitis noninfective probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Bloating possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eye disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Eosinophilia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Bullous dermatitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dry mouth possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Weight loss possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Eosinophilia probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to research	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Gastrointestinal disorders Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Sinus tachycardia possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction definitely related to M7824	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hoarseness possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders - Other specify probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hematuria probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Diarrhea possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Myalgia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Serum amylase probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Neutrophil count decreased	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Anktiva (N803)	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vertigo possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Lipase increased probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pain possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular probably related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Urticaria probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Vomiting possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proteinuria possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Aspartate aminotransferase increased probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fatigue possibly related to Anktiva (N803)0	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Abdominal pain possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction definitely related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alkaline phosphatase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Proctitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Vomiting possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alkaline phosphatase increased probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased probably related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Lipase increased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Nausea possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Skin and subcutaneous tissue disorders Other, specify, probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 injection site reaction definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fever possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Injection site reaction probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Joint range of motion decreased possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Anorexia possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Dizziness probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Chills probably related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Blood and lymphatic system disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Alanine aminotransferase increased possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dry mouth possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Endocrine disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Infusion related reaction probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hematuria probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypothyroidism probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 General disorders& administration site conditions Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Mucositis oral possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Diarrhea possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Enterocolitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Generalized muscle weakness possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Alanine aminotransferase increased possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash acneiform probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to research	4 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Chills possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus possibly related to Epacadostat	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Lipase increased probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pancreatitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flatulence possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Fever probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Arthralgia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculopapular possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular probably related to research	3 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus definitely related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Neoplasms benign, malignant and unspecified incl cysts and polyps probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gingival pain probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Pruritus probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Blood and lymphatic system disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hemolysis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Skin and subcutaneous tissue disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Flu-like symptoms possibly related to Bavarian-Nordic (BN)-brachyury	2 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperthyroidism probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 General disorders& administration site conditions Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Dehydration possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hyperhidrosis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Headache possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anorexia possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Infusion related reaction definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Mucositis oral possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hyperthyroidism probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Hypothyroidism definitely related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Epistaxis possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Rash maculo-papular possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Injection site reaction definitely related to research	6 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Epacadostat	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Anal hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Arthritis definitely related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Insomnia possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Fatigue possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Weight loss possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Rash maculo-papular possibly related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Oral hemorrhage probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Gastrointestinal disorders - Other specify probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Eye disorders Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Pruritus probably related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Pruritus probably related to Anktiva (N803)	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Endocrine disorders - Other specify possibly related to Bavarian-Nordic (BN)-brachyury	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 2 Hypotension possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Rash maculo-papular probably related to Anktiva (N803)	4 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 1 Malaise possibly related to Bavarian-Nordic (BN)-brachyury	0 Participants

Secondary

Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)

Number of participants with grades 3 4, and/or 5 serious adverse events related to treatment treated with combinations and Bintrafusp alfa (M7824) + Anktiva (N-803).

Time frame: 3 weeks dose-limiting toxicity (DLT) period

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to Anktiva (N-803)	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to research	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 5 related to research and/or any study treatment	0 Participants
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to Anktiva (N-803)	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to research	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 5 related to research and/or any study treatment	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to M7824	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to M7824	1 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to research	0 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to Anktiva (N-803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 5 related to research and/or any study treatment	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 5 related to research and/or any study treatment	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to Anktiva (N-803)	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to research	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to M7824	1 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to M7824	1 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to research	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 5 related to research and/or any study treatment	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to Anktiva (N-803)	0 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to Anktiva (N-803)	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 5 related to research and/or any study treatment	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Endocrine disorders - Other specify probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 4 Blood and lymphatic system disorders - Other specify possibly related to research	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Metabolism and nutrition disorders - Other, specify possibly related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Enterocolitis probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage probably related to M7824	0 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)	Grade 3 Tumor hemorrhage possibly related to research	0 Participants

Other Pre-specified

Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame: Adverse Events were monitored/assessed from the first study intervention, up to 49 weeks.

Population: 58/59 participants were analyzed because one was deemed ineligible.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	4 Participants
All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	10 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	13 Participants
Phase IIA Dose Expansion, Cohort 2, Arm 2.2A	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	13 Participants
Phase IIB, Dose Expansion, Cohort 2, Arm 2.2B	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	12 Participants
Phase IIA Dose Expansion, Cohort 2A, Arm 2.3A	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	6 Participants

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Other

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Clinical Benefit(Objective Response if Measurable Disease by Response Evaluation Criteria in Solid Tumors v1.1)With Any of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer Reported With a 95% Confidence Interval

Clinical Benefit With Any of a Set of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Reported With an 80% Confidence Interval

Phase I/II: Number of Participants With Grades 3, 4, and/or 5 Serious and/or Non-serious Dose-limiting Toxicities (DLT)

6-month Progression Free Survival (PFS) Probability

Number of Participants With Grades 1, 2, 3, and 4 Non-serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)

Number of Participants With Grades 3, 4, and/or 5 Serious Adverse Events Related to Treatment Treated With Combinations and Bintrafusp Alfa (M7824) + Anktiva (N-803)

Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)